EMCDDA

The EMCDDA and the University Institute of Lisbon (ISCTE-IUL) are delighted to open registration today for two upcoming joint events in 2023: the European Drugs Winter School (EDWS) and the European Drugs Summer School (EDSS) (1)(2). EDWS...

Overview Mental health problems are very common in those with a substance use disorder, and these patients have more clinically and psychosocially severe problems than patients with substance use disorders without comorbid mental health...

Between March and May 2021, the EU4Monitoring Drugs (EU4MD) project supported the mapping of national prevention systems in European Neighbourhood Policy (ENP) area countries. This briefing describes the rationale and methodology of the...

This toolkit aims to support the EMCDDA’s stakeholders, other actors and researchers in the drugs field to implement their own foresight exercise in the form of an introductory trend-based workshop. It describes briefly the foresight and...

Overview A new psychoactive substance (NPS) is defined as 'a new narcotic or psychotropic drug, in pure form or in preparation, that is not controlled by the United Nations drug conventions, but which may pose a public health threat...

This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of what to consider when planning or delivering health and social responses to drug...

A new handy mini guide by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on evidence-based policymaking for prevention of drug use in schools and educational settings.

Today, the European Commission has adopted measures to control two harmful new psychoactive substances (NPS) across the EU. The substances in question — 3-methylmethcathinone (3-MMC) and 3-chloromethcathinone (3-CMC) — are both synthetic...